deucrictibant extended-release tablets — NDA/BLA submission
1H2027
U.S. NDA Submission: 1H2027Source filing
PHVS biotech catalysts & pipeline
PHARVARIS NV · Data as of 2026-10-25
Upcoming catalysts
deucrictibant XR (PHVS719) — Topline data
Q1 2027
Topline data from Part 1 of CREAATE ( NCT07266805 ), a global, pivotal Phase 3 study evaluating orally-administered deucrictibant XR for the prevention of AAE-C1INH attacks, are anticipated in the first quarter of 2027.Source filing
deucrictibant XR (PHVS719) — Initial data
1Q2027
Part 1 Topline Data:1Q2027Source filing
deucrictibant XR (PHVS719) — NDA/BLA submission
H1 2027
Data from the CHAPTER-3 study will serve as the basis for marketing authorization applications, which are planned to be submitted starting in the first half of 2027.Source filing
deucrictibant immediate-release capsules — PDUFA
Apr 23
FDA PDUFA goal April 23, 2027Source filing
deucrictibant IR (PHVS416) — PDUFA
Apr 23
FDA PDUFA goal April 23, 2027 U.S. ODT LaunchSource filing